Skip to main
HOWL
HOWL logo

Werewolf Therapeutics (HOWL) Stock Forecast & Price Target

Werewolf Therapeutics (HOWL) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Werewolf Therapeutics Inc. has demonstrated a robust safety profile for its lead candidates WTX-330 and WTX-124, with manageable treatment-emergent adverse events that are primarily mild to moderate, which supports a favorable outlook for further clinical development. The company's proprietary PREDATOR platform offers a novel approach to cancer treatment by designing conditionally activated molecules, which not only enhance safety and efficacy but also improve dosing flexibility, thereby expanding potential therapeutic applications beyond oncology. Additionally, encouraging preclinical results, including promising monotherapy activity and response rates in various cancer types, highlight the potential for Werewolf's therapeutics to address significant limitations of current treatments in the market.

Bears say

Werewolf Therapeutics encountered a significant net loss of $20.4 million in the fourth quarter of 2024, which represented an increase from $12.0 million in the same period the previous year, indicating potential financial distress. There are notable risks associated with the company's lead candidate WTX-124, including possible clinical or regulatory setbacks, and concerns regarding its ability to achieve acceptable safety and efficacy profiles, which could hinder its market potential. Additionally, the company’s expansion opportunities may not be adequately valued by the market, contributing to an overall negative sentiment surrounding its financial outlook.

Werewolf Therapeutics (HOWL) has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Werewolf Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Werewolf Therapeutics (HOWL) Forecast

Analysts have given Werewolf Therapeutics (HOWL) a Buy based on their latest research and market trends.

According to 8 analysts, Werewolf Therapeutics (HOWL) has a Buy consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.04, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.04, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Werewolf Therapeutics (HOWL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.